Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02926911 · ClinicalTrials.gov registry record · NA
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS
A NA study of Ductal Carcinoma In Situ and DCIS, sponsored by Alliance Foundation Trials.
- Active
- Registry status
- NA
- Development phase
- 997
- Enrollment target
- 20
- Study locations
NCT02926911: Active NA study of Ductal Carcinoma In Situ and DCIS, sponsored by Alliance Foundation Trials.
NCT02926911 is a NA study of Ductal Carcinoma In Situ and DCIS that is active but no longer recruiting, run by Alliance Foundation Trials. The registered enrollment target is 997 participants, above the 191-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (422% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02926911, a NA study of Ductal Carcinoma In Situ and DCIS, is active but no longer recruiting, sponsored by Alliance Foundation Trials.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 997 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study looks at the risks and benefits of active monitoring (AM) compared to surgery in the setting of a pragmatic prospective randomized trial for low risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AM approach does not yield inferior cancer or quality of life outcomes compared to surgery.
Primary Outcome
To compare the number of patients that develop ipsilateral invasive cancer that received surgery to the number of patients that were placed on active monitoring after 2 years of follow-up
Conditions Studied
Interventions
- OTHER Surgery
- OTHER Active Monitoring
Study Locations (20)
Illinois
- John H Stroger Jr Hospital of Cook County - Chicago
- University of Chicago Medical Center - Chicago
- Advocate Illinois Masonic Medical Center - Chicago
- NorthShore University HealthSystem-Evanston Hospital - Evanston
- Ingalls Memorial Hospital - Harvey
- Illinois Cancer Care - Peoria
California
- City of Hope - Duarte
- Cedars-Sinai Medical Center - Los Angeles
- Sharp Memorial Hospital - San Diego
- Kaiser Permanente Medical Center - Vallejo
Colorado
- Colorado Cancer Research Program - Denver
- Saint Joseph Hospital- Cancer Centers of Colorado - Lafayette
Florida
- Memorial Healthcare System - Hollywood
- Mayo Clinic Florida - Jacksonville
Alaska
- Providence Alaska Medical Center - Anchorage
Arizona
- Mayo Clinic - Phoenix
Connecticut
- Smilow Cancer Hospital at Yale-New Haven - New Haven
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 997 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2030-07 |
| Phase | NA |
What the registry record for NCT02926911 still lists
NCT02926911 is an interventional study that assigns participants to a tested intervention. The registered 997 participants enrollment target is mid-sized for trials with a published cap, above the 191-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (422% higher).
The record links to 2 conditions, with Ductal Carcinoma In Situ appearing as the primary indexed condition, and to 2 interventions - of which Surgery is the first listed.
NCT02926911 names 20 study sites across 10 states, led by Illinois, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02926911 about?
NCT02926911 is a clinical study titled "Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS". This study looks at the risks and benefits of active monitoring (AM) compared to surgery in the setting of a pragmatic prospective randomized trial for low risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AM approach does not yield inferio...
What is the current status of trial NCT02926911?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 997 participants. The study started on 2017-02-22. Estimated completion is 2030-07.
What conditions does trial NCT02926911 study?
This clinical trial studies the following conditions: Ductal Carcinoma In Situ, DCIS.
What interventions are being tested in trial NCT02926911?
The interventions under investigation include: Surgery (OTHER), Active Monitoring (OTHER).
Who is sponsoring clinical trial NCT02926911?
This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02926911 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ductal Carcinoma In Situ
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02926911's enrollment target sits among peer trials
997 2nd of 15 the highest of 15 other Ductal Carcinoma In Situ trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ductal Carcinoma In Situ trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
RECRUITING · NA
-
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
RECRUITING · NA
-
Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
RECRUITING · NA
-
Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®
ACTIVE NOT RECRUITING · NA
-
Intraoperative Radiation Therapy (IORT) in DCIS
ACTIVE NOT RECRUITING · NA
-
Living Well After Breast Surgery
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07005024 · 996 participants · Phase 3
DOAC - Dosing Options in AntiCoagulation Prophylaxis
- NCT02986048 · 999 participants
Proton Therapy Patient Registry
- NCT04703244 · 999 participants
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI